查看购物车
  • Traditional Chinese
  • English
  • Japanese
流感疫苗市场规模、份额和成长分析（按疫苗类型、疫苗配方、技术、给药途径、年龄层、分销管道和地区划分）－2026-2033年产业预测
市场调查报告书
商品编码
1897805

流感疫苗市场规模、份额和成长分析（按疫苗类型、疫苗配方、技术、给药途径、年龄层、分销管道和地区划分）－2026-2033年产业预测

Influenza Vaccine Market Size, Share, and Growth Analysis, By Vaccine Type (Quadrivalent, Trivalent), By Vaccine Formulation, By Technology, By Route of Administration, By Age Group, By Distribution Channel, By Region - Industry Forecast 2026-2033
出版日期: | 出版商: SkyQuest | 英文 200 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计到 2024 年，全球流感疫苗市场规模将达到 79.1 亿美元，到 2025 年将成长至 84.6 亿美元，到 2033 年将成长至 145.2 亿美元，在预测期（2026-2033 年）内，复合年增长率为 6.98%。

流感病毒持续在全球传播，导致局部地区持续爆发疫情，死亡率居高不下。疫苗株的年度更新对于应对病毒变异至关重要。随着流感疫情日益频繁，全球权威卫生机构推荐的流感疫苗需求显着增加。世界各国政府正积极进行疫苗接种宣传活动，以最大限度地提高流感季的防护效果。同时，製药公司在研发针对特定株的有效疫苗方面面临持续的挑战。疫情的不断蔓延，以及对创新疫苗解决方案的持续需求，预计将推动流感疫苗市场显着增长，而消费者对有效流感疫苗的需求不断增加正是这一增长的主要驱动力。

全球流感疫苗市场驱动因素

全球流感疫苗市场主要受政府支持和旨在加强疫苗接种工作的监测活动所推动。在国家和国际层面进行有效的监测对于监管流感疫苗的供应链、分发和接种至关重要。世界卫生组织（世卫组织）等机构与各国政府合作，积极追踪疫苗需求，并在全球实施疫苗接种计划，以优化各地区的疫苗供应。这种协调一致的努力确保了充足的疫苗供应，以满足公共卫生需求，并促进流感疫苗的广泛接种。

限制全球流感疫苗市场的因素

全球流感疫苗市场面临许多限制因素，主要源自于疫苗研发过程的漫长和复杂，需要对疫苗的安全性、品质和有效性进行全面评估。国际临床试验的复杂性以及各国不同的法规结构常常阻碍这一进程。由于监管机构通常需要来自多个地区的大量数据，这些差异可能导致新疫苗上市时间的显着延迟。此外，不同的标籤标准和紧迫的试验时间进一步增加了全球临床试验的难度。因此，这些严格的要求和漫长的试验週期可能会阻碍产品研发的进展。

全球流感疫苗市场趋势

受新冠疫情后公众健康意识提升的推动，全球流感疫苗市场呈现正面趋势。流感疫苗接种率的激增主要归功于医疗专业人员加强宣传教育以及各国政府在各地推广免费疫苗接种计划。因此，已开发国家和开发中国家的流感疫苗宣传活动率均有所提高。此外，人们对预防性医疗保健价值的日益重视，并持续推动疫苗研发领域的投资，最终促进了流感疫苗市场更加强劲、更具活力。

目录

介绍

  • 调查目标
  • 调查范围
  • 定义

调查方法

  • 资讯收集
  • 二手资料和一手资料方法
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 全球市场展望
  • 供需趋势分析
  • 细分市场机会分析

市场动态与展望

  • 市场规模
  • 市场动态
    • 驱动因素和机会
    • 限制与挑战
  • 波特分析

关键市场考察

  • 关键成功因素
  • 竞争程度
  • 关键投资机会
  • 市场生态系统
  • 市场吸引力指数（2025）
  • PESTEL 分析
  • 总体经济指标
  • 价值链分析
  • 定价分析
  • 技术进步
  • 监管环境
  • 案例研究
  • Start-Ups分析
  • 专利分析

全球流感疫苗市场规模（依疫苗类型划分）及复合年增长率（2026-2033 年）

  • 四价
  • 三价

全球流感疫苗市场规模（依疫苗配方及复合年增长率划分）（2026-2033 年）

  • 灭活疫苗
  • 减毒活病毒疫苗

全球流感疫苗市场规模（依技术及复合年增长率划分）（2026-2033 年）

  • 鸡蛋生产
  • 细胞培养生产
  • 基于重组的生产

全球流感疫苗市场规模（依给药途径及复合年增长率划分）（2026-2033 年）

  • 注射
  • 鼻喷剂

全球流感疫苗市场规模（依年龄层划分）及复合年增长率（2026-2033 年）

  • 儿童
  • 成人版
  • 对于老年人

全球流感疫苗市场规模（依分销管道划分）及复合年增长率（2026-2033 年）

  • 医院和药房
  • 政府和机构用品
  • 其他的

全球流感疫苗市场规模及复合年增长率（2026-2033）

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲
    • 海湾合作委员会国家
    • 南非
    • 其他中东和非洲地区

竞争资讯

  • 前五大公司对比
  • 主要企业的市场定位（2025 年）
  • 主要市场参与者所采取的策略
  • 近期市场趋势
  • 公司市占率分析（2025 年）
  • 主要企业公司简介
    • 公司详情
    • 产品系列分析
    • 依业务板块进行公司股票分析
    • 2023-2025年营收年比比较

主要企业简介

  • Sanofi Pasteur（France）
  • GlaxoSmithKline plc（GSK, UK）
  • Seqirus（CSL, Australia）
  • Pfizer Inc.（USA）
  • AstraZeneca PLC（UK）
  • Novavax, Inc.（USA）
  • Bharat Biotech（India）
  • Johnson & Johnson（USA）
  • Sinovac Biotech（China）
  • Bio Farma（Indonesia）
  • Serum Institute of India（India）
  • Abbott Biologicals BV（Netherlands）
  • Adimmune Corporation（Taiwan）
  • BIKEN Co., Ltd.（Japan）
  • Changchun BCHT Biotechnology（China）
  • Valneva SE（France）
  • Scinai Immunotherapeutics Ltd（Israel）
  • Moderna, Inc.（US）
  • Altimmune, Inc.（USA）
  • Osivax（France）

结论与建议

简介目录
Product Code: SQMIG35B2144

Global Influenza Vaccine Market size was valued at USD 7.91 Billion in 2024 and is poised to grow from USD 8.46 Billion in 2025 to USD 14.52 Billion by 2033, growing at a CAGR of 6.98% during the forecast period (2026-2033).

The influenza virus continues to circulate globally, leading to persistent regional epidemics and outbreaks with significant mortality rates. An annual adaptation of the vaccine strain is necessary to align with the evolving nature of the virus. As the frequency of influenza outbreaks rises, there is a notable increase in the demand for influenza vaccines, which are recommended by reputable health organizations globally. Governments are actively promoting vaccination campaigns to maximize protection during flu seasons. Concurrently, pharmaceutical companies face ongoing challenges in developing effective vaccines tailored to specific strains. This combination of rising epidemic prevalence and the continuous need for innovative vaccine solutions positions the Influenza Vaccine Market for substantial growth driven by heightened consumer demand for effective influenza vaccination.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Influenza Vaccine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Influenza Vaccine Market Segments Analysis

Global Influenza Vaccine Market is segmented by Vaccine Type, Vaccine Formulation, Technology, Route of Administration, Age Group, Distribution Channel and region. Based on Vaccine Type, the market is segmented into Quadrivalent and Trivalent. Based on Vaccine Formulation, the market is segmented into Inactivated and Live Attenuated. Based on Technology, the market is segmented into Egg-based Production, Cell-based Production and Recombinant-based Production. Based on Route of Administration, the market is segmented into Injection and Nasal Spray. Based on Age Group, the market is segmented into Pediatric, Adult and Geriatric. Based on Distribution Channel, the market is segmented into Hospital & Pharmacies, Government & Institutional Supply and Other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Influenza Vaccine Market

The global market for influenza vaccines is significantly driven by the rising support and surveillance efforts from governments aimed at enhancing vaccination initiatives. Effective monitoring at both national and international levels is essential for overseeing the supply chain, distribution, and administration of influenza vaccines. Organizations such as the World Health Organization, in partnership with various governments, actively track vaccine demand and implement immunization programs worldwide to optimize vaccine availability in diverse regions. This concerted effort helps ensure that adequate vaccine supplies are maintained, thereby addressing public health needs and promoting widespread vaccination against influenza.

Restraints in the Global Influenza Vaccine Market

The global influenza vaccine market faces significant restraints primarily due to the prolonged and intricate nature of vaccine development, which necessitates meticulous evaluation of safety, quality, and efficacy. This process is often hindered by the complexities associated with global clinical studies and the varying regulatory frameworks imposed by different countries. These discrepancies can lead to substantial delays in the introduction of new vaccines, as regulatory bodies frequently require extensive data from multiple regions. Additionally, differing labeling standards and compressed timelines further complicate the execution of clinical trials on a global scale. As a result, these stringent requirements and the extended duration for trial conduct may impede progress in product development.

Market Trends of the Global Influenza Vaccine Market

The Global Influenza Vaccine market is witnessing a positive trend, driven by heightened awareness of public health measures in the wake of the coronavirus pandemic. This surge in flu vaccination rates is largely attributed to intensified advocacy from health experts and government initiatives promoting free vaccination programs across diverse regions. Consequently, both developed and developing nations have observed an uptick in participation in flu immunization campaigns. Furthermore, the growing recognition of the value of preventive healthcare continues to propel investments in vaccine research and development, ultimately fostering a more robust and responsive influenza vaccine market landscape.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2025
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Technological Advancement
  • Regulatory Landscape
  • Case Studies
  • Startup Analysis
  • Patent Analysis

Global Influenza Vaccine Market Size by Vaccine Type & CAGR (2026-2033)

  • Market Overview
  • Quadrivalent
  • Trivalent

Global Influenza Vaccine Market Size by Vaccine Formulation & CAGR (2026-2033)

  • Market Overview
  • Inactivated
  • Live Attenuated

Global Influenza Vaccine Market Size by Technology & CAGR (2026-2033)

  • Market Overview
  • Egg-based Production
  • Cell-based Production
  • Recombinant-based Production

Global Influenza Vaccine Market Size by Route of Administration & CAGR (2026-2033)

  • Market Overview
  • Injection
  • Nasal Spray

Global Influenza Vaccine Market Size by Age Group & CAGR (2026-2033)

  • Market Overview
  • Pediatric
  • Adult
  • Geriatric

Global Influenza Vaccine Market Size by Distribution Channel & CAGR (2026-2033)

  • Market Overview
  • Hospital & Pharmacies
  • Government & Institutional Supply
  • Other

Global Influenza Vaccine Market Size & CAGR (2026-2033)

  • North America (Vaccine Type, Vaccine Formulation, Technology, Route of Administration, Age Group, Distribution Channel)
    • US
    • Canada
  • Europe (Vaccine Type, Vaccine Formulation, Technology, Route of Administration, Age Group, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Vaccine Type, Vaccine Formulation, Technology, Route of Administration, Age Group, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Vaccine Type, Vaccine Formulation, Technology, Route of Administration, Age Group, Distribution Channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Vaccine Type, Vaccine Formulation, Technology, Route of Administration, Age Group, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • Sanofi Pasteur (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc (GSK, UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Seqirus (CSL, Australia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca PLC (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novavax, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bharat Biotech (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sinovac Biotech (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bio Farma (Indonesia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Serum Institute of India (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Abbott Biologicals B.V. (Netherlands)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Adimmune Corporation (Taiwan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BIKEN Co., Ltd. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Changchun BCHT Biotechnology (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Valneva SE (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Scinai Immunotherapeutics Ltd (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Moderna, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Altimmune, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Osivax (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations